摘要
目的:比较基因重组人胰岛素与人胰岛素类似物以胰岛素泵为输入载体时对于2型糖尿病胰岛素抵抗的疗效。方法:34例2型糖尿病胰岛素抵抗的患者随机分为两组:诺和锐治疗组及诺和灵对照组各17例,均为使用胰岛素强化治疗血糖控制不佳的胰岛素抵抗患者。根据毛细血糖监测结果调整胰岛素用量,比较两组血糖达标后每日药量及达标所需时间。结果:治疗组达标后每日药量及达标所需时间均显著少于对照组。结论:胰岛素泵诺和锐治疗2型糖尿病胰岛素抵抗的疗效明显优于胰岛素泵诺和灵。
Objective： To investigate the clinical efficacy of insulin aspart in the treatment of type 2 diabetes with insulin resistance by continuous subcutaneous aspart injection with insulin pump. Methods： Thirty-four cases of type 2 diabetes with insulin resistance were randomly divided into insulin aspart treatment group and novolin R control group, with 17 cases in each group. All the patient were type 2 diabetic patients with insulin resistance whose target blood glucose （BG） levels failed to be well controlled by insulin intensification therapy. We adjusted the dose of insulin aspart according to the capillary blood glucose, and compared the insulin dose, blood glucose level and control time in both groups when the blood glucose was stabilized. Results： The blood glucose could be better controlled in the insulin aspart group with insulin pump, compared with the novolin R control group. Conclusion： The effectiveness of insulin aspart with insulin pump is superior to that of novolin R in the treatment of type 2 diabetes with insulin resistance.
出处
《黑龙江医药科学》
2006年第2期53-54,共2页
Heilongjiang Medicine and Pharmacy
关键词
胰岛素泵
诺和锐
2型糖尿病
胰岛素抵抗
insulin pump
insulin aspart
type 2 diabetes
insulin resistance （IR）
